To evaluate efficacy, safety, and tolerability of BI 655130 compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity
|Treatment||Placebo, BI 655130, Spesolimab|
|Clinical Study Identifier||NCT03782792|
|Last Modified on||22 November 2020|
Select a piece of text and start making personal notes.
Congrats! You have your own personal workspace now.